FDA Drug recall D-0772-2021
Atovaquone Oral Suspension, USP, 750 mg/5 mL, 210 mL bottle, Rx Only, Mfd
- FDA Drug
- Class I
- terminated
- Published 2021-09-01
On 2021-09-01 the FDA classified a Class I recall of Atovaquone Oral Suspension, USP, 750 mg/5 mL, 210 mL bottle, Rx Only, Mfd by Kvk Tech, citing temperature abuse: the firm received customer complaints of unusual grittiness in the product.
Read the official FDA Drug notice
| Agency | FDA Drug |
|---|---|
| Recall number | D-0772-2021 |
| Classification | Class I |
| Status | terminated |
| Initiated | 2021-07-02 |
| Published | 2021-09-01 |
| Last updated | 2026-09-13 11:52 UTC |
| Company | Kvk Tech |
| Distribution | US |
Product
Atovaquone Oral Suspension, USP, 750 mg/5 mL, 210 mL bottle, Rx Only, Mfd. By: KVK-Tech, Inc., Newtown, PA 18940, NDC 10702-223-21.
Reason
Temperature abuse: the firm received customer complaints of unusual grittiness in the product.
Identifiers
| ndc | 10702-223-21 |
|---|---|
| code_info | Batch # 16653A, 16654A, Exp 12/2022 |
Status history
No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:52 UTC. Current status: terminated.
Source
Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0772-2021%22
RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.